Are BTK and PLCG2 mutations required and enough for ibrutinib resistance in Serious lymphocytic leukemia? Serious lymphocytic leukemia (CLL) is often a lymphoid malignancy characterised through the proliferation and accumulation of experienced CD5+ B cells in the blood, bone marrow and lymphoid tissues. The prognosis of CLL calls for the https://clarencen888mih3.blogrelation.com/profile